EnVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO), a company focused on venous disease treatments, announced the pricing of a $15.0 million underwritten public offering. Existing institutional investors will purchase 4,285,715 shares of common stock at $3.50 per share, or pre-funded warrants. These warrants are immediately exercisable at $0.0001 per share.

Titan Partners Group is acting as the sole bookrunner. enVVeno expects gross proceeds, excluding the underwriter's option, to be $15.0 million. The offering is set to close around September 30, 2024. The proceeds will primarily fund the development of VenoValve and enVVe, and for general corporate purposes.

The securities are offered via a prospectus supplement and base prospectus filed with the SEC as part of a shelf registration statement (File No. 333-273546). These documents are available on the SEC's website.